Disclosure: M.J. Huvard, None; J.L. Patnaik, None; D.M. Kleinman, Ascidian Therapeutics (C), AGTC (C), Aprea Therapeutics (C), Cleave Therapeutics (C), Coherus BioSciences (C), Design Therapeutics (C), Editas Medicine (C), Emergent Product Development (C), GSK, Helixmith USA (C), Kala Pharmaceuticals (C), Olema Pharmaceuticals (C), ONL Therapeutics (C, P, I), Prime Medicine (C), Revolution Medicines (C), Triphase Accelerator (C), Calm Water Therapeutics (P, S, I); M. Preston, None; D.N. Zacks, ONL Therapeutics (F, C, P); A.J. Kocab, ONL Therapeutics (F, E, P); J. van de Goor, ONL Therapeutics (F, C, P); B.D. Wagner, None; S. Cho, None; A.M. Lynch, None; N. Mandava, None